Literature DB >> 31626823

Tuberculosis control in crisis-causes and solutions.

Gilla Kaplan1.   

Abstract

Tuberculosis (TB) incidence is projected to decline at too slow a rate to meet the targets set at the UN high level meeting on ending TB, convened in New York in 2018. To understand the causes of the slow progress in TB control, the Bill and Melinda Gates Foundation supported a patient-pathway analysis that identified significant gaps with patients being "lost" at all points along the care cascade. Although each country differed in the reasons for failure, some commonalities were identified. Most striking was the failure to diagnose and report TB patients to a national registry making finding the missing patients a priority for TB control globally. The analysis also found that optimal use of existing tools will not accelerate the rate of decline in TB incidence sufficiently, necessitating the development of new and improved tools for TB control. Finally, it was recognized that gaps in our understanding of TB pathogenesis and protective immunity as well as limited knowledge about the host pathogen interactions in granulomas of infected tissues, hinder the progress needed to develop the new tools for improved TB control. A commitment of all governments to support research, develop new tools such as new diagnostics, better drug regimens and efficacious vaccines, and improving service delivery by TB control programs will be needed to accelerate the reduction in incidence and reduce disease burden globally.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Global epidemic; Multidrug resistant tuberculosis; Patient pathway analysis; Tuberculosis; Tuberculosis control

Mesh:

Substances:

Year:  2019        PMID: 31626823     DOI: 10.1016/j.pbiomolbio.2019.10.001

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  4 in total

1.  Recombinant Human Lactoferrin Reduces Inflammation and Increases Fluoroquinolone Penetration to Primary Granulomas During Mycobacterial Infection of C57Bl/6 Mice.

Authors:  Thao K T Nguyen; Zainab Niaz; Marian L Kruzel; Jeffrey K Actor
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-02-28       Impact factor: 4.291

2.  Capture and visualization of live Mycobacterium tuberculosis bacilli from tuberculosis patient bioaerosols.

Authors:  Ryan Dinkele; Sophia Gessner; Andrea McKerry; Bryan Leonard; Ronnett Seldon; Anastasia S Koch; Carl Morrow; Melitta Gqada; Mireille Kamariza; Carolyn R Bertozzi; Brian Smith; Courtney McLoud; Andrew Kamholz; Wayne Bryden; Charles Call; Gilla Kaplan; Valerie Mizrahi; Robin Wood; Digby F Warner
Journal:  PLoS Pathog       Date:  2021-02-01       Impact factor: 6.823

Review 3.  One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics.

Authors:  Hee-Jeong Yang; Decheng Wang; Xin Wen; Danielle M Weiner; Laura E Via
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

4.  Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832.

Authors:  Gregory T Robertson; Michelle E Ramey; Lisa M Massoudi; Claire L Carter; Matt Zimmerman; Firat Kaya; Barbara G Graham; Veronica Gruppo; Courtney Hastings; Lisa K Woolhiser; Dashick W L Scott; Bryce C Asay; Franceen Eshun-Wilson; Ekaterina Maidj; Brendan K Podell; Joshua J Vásquez; Mike A Lyons; Véronique Dartois; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.